Vascular biology support for the use of bevacizumab in colorectal cancer

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 703-705

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Bevacizumab; Colorectal cancer; Tumour vascular biology; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN; MONOCLONAL ANTIBODY; PLACEBO; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; BLOOD VOLUME; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; EPISTAXIS; HUMAN; HYPERTENSION; HYPONATREMIA; INTERSTITIAL FLUID; METASTASIS; PRESSURE; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; RECTUM CARCINOMA; THROMBOSIS; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3042761608     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.703     Document Type: Article

References (11)

1. WILLETT CG, BOUCHER E, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10:145-147.
2. DVORAK HF: Vascular permeability factor/endothelial growth factor, a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. (2002) 20:4368-4380.
3. + stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8:841-849.
4. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
5. YUAN F, CHEN Y, DELLIAN M et al.: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93:14765-14770.
6. LEE C-G, HEIJY M, DI TOMASO E et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. (2000) 60:5565-5570.
7. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19:843-850.
8. COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al. A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. (2003) 30(5 Suppl. 16):117-124.
9. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
10. McCARTHY M: Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet (2003) 361:1959.
11. MANCUSO P, BURLINI A, PRUNERI G et al.: Resting and activated endothelial cells are increased in the peripheral blood of cancer cells. Blood (2001) 97:3658-3661.